We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

* As of Jan. 2023

Pipeline Chart

3 ADCs

  • Trastuzumab deruxtecan (T-DXd)
  • Patritumab deruxtecan (HER3-DXd)
  • Datopotamab deruxtecan (Dato-DXd)

AGA: actionable genomic alterations, BC: breast cancer, CRPC: castration-resistant prostate cancer, CRC: colorectal cancer, GC: gastric cancer,NSCLC: non-small celllung cancer, SCLC: small celllung cancer, TNBC: triple negative breast cancer

  • : Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
  • : Breakthrough designation (US)
  • : Orphan drug designation (JP)

Phase 1

  • (US/EU/Asia) HER2+ BC 2L+/ 1L
    DESTINY-Breast07
  • (US/EU/Asia) HER2 low BC
    Chemo naive/post chemo
    DESTINY-Breast08
  • (JP/US/EU/Asia) HER2+ GC combo, 2L+/1L
    DESTINY-Gastric03
  • (EU/Asia) HER2+ NSCLC
    (durvalumab combo) 1L
    DESTINY-Lung03
  • (US/EU) BC, bladder (nivolumab combo)
  • (US/EU) BC, NSCLC
    (pembrolizumab combo)
  • (US/EU/Asia) solid tumors
    (AZD5305 combo)
    PETRA
  • (JP/US) NSCLC, TNBC
    BC*1, SCLC, GC,
    urothelial, esophageal,
    prostate, etc.
    TROPION-PanTumor01
  • (CN) NSCLC, TNBC
    TROPION-PanTumor02
  • (JP/US/EU/Asia) NSCLC
    (w/o AGA, pembrolizumab
    combo)
    TROPION-Lung02
  • (JP/US/EU) NSCLC
    (w/o AGA, durvalumab combo)
    TROPION-Lung04
  • (JP/US/EU/Asia) solid tumors
    (AZD5305 combo)
    PETRA
  • (JP/US/EU/Asia) NSCLC
  • (JP/US) EGFR mutated
    NSCLC (osimertinib combo)
  • (JP/US) HER3+ BC

Phase 2

  • (US/EU/Asia) TNBC
    (durvalumab combo)
    BEGONIA
  • (CN) HER2+ GC 3L
    DESTINY-Gastric06
  • (JP/US/EU) HER2+ or HER2 mutant NSCLC 2L+
    DESTINY-Lung01
  • (JP/US/EU/Asia) HER2 mutant NSCLC 2L+
    DESTINY-Lung02
  • (CN) HER2 mutant NSCLC 2L+
    DESTINY-Lung05
  • (US/EU/Asia) NSCLC
    (durvalumab combo) 2L+
    HUDSON
  • (JP/US/EU) HER2+ CRC 3L
    DESTINY-CRC01
  • (JP/US/EU/Asia) HER2+ CRC 3L
    DESTINY-CRC02
  • (JP/US/EU/Asia)
    HER2 mutant tumor
    DESTINY-PanTumor01
  • (US/EU/Asia)
    HER2 expressing tumor
    DESTINY-PanTumor02
  • (JP/US/EU/Asia) endometrial, ovarian, CRPC, GC, CRC combo
    TROPION-PanTumor03
  • (JP/US/EU/Asia) NSCLC
    (w/ AGA)
    TROPION-Lung05
  • (US/EU/Asia) TNBC
    (durvalumab combo)
    BEGONIA
  • (JP/US/EU/Asia) EGFR mutated NSCLC
    (osimertinib combo) 2L
    ORCHARD
  • (JP/US/EU/Asia)
    EGFR mutated NSCLC 3L
    HERTHENA-Lung01

Phase 3

  • (JP/US/EU/Asia) HER2+ BC 3L
    DESTINY-Breast02
  • (JP/US/EU/Asia) HER2+
    BC adjuvant*2
    DESTINY-Breast05
  • (JP/US/EU/Asia) HER2
    low BC chemo naive
    DESTINY-Breast06
  • (JP/US/EU/Asia) HER2+
    BC 1L
    DESTINY-Breast09
  • (JP/US/EU/Asia) HER2+
    BC neoadjuvant
    DESTINY-Breast11
  • (JP/EU/Asia) HER2+
    GC 2L
    DESTINY-Gastric04
  • (JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L
    DESTINY-Lung04
  • (JP/US/EU/Asia) NSCLC 2/3L
    TROPION-Lung01
  • (JP/US/EU/Asia) non-squamous NSCLC
    (w/o AGA, pembrolizumab
    combo) 1L
    TROPION-Lung07
  • (JP/US/EU/Asia) NSCLC
    (w/o AGA, pembrolizumab
    combo) 1L
    TROPION-Lung08
  • (JP/US/EU/Asia) BC*1 2/3L
    TROPION-Breast01
  • (JP/US/EU/Asia) TNBC 1L
    TROPION-Breast02
  • (JP/US/EU/Asia) TNBC
    mono or durvalumab
    combo) adjuvant*3
    TROPION-Breast03
  • (JP/US/EU/Asia) EGFR mutated
    NSCLC 2L
    HERTHENA-Lung02

Submitted

  • (CN) HER2+ BC 2L
    DESTINY-Breast03
  • (JP/CN) HER2 low BC
    post chemo
    DESTINY-Breast04
  • (JP/EU) HER2 mutant NSCLC 2L+
    DESTINY-Lung01/Lung02

 

*1 HR+, HER2 low or negative BC
*2 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy
*3 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy

Alpha

  • Oncology
  • Specialty Medicine
  • Vaccine

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma,FOP: Fibrodysplasia ossificans progressiva, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma

  • : Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
  • : SAKIGAKE Designation (JP)
  • : Orphan drug designation (designated in at least one country/region among JP, US, and EU)

Phase 1

  • DS-7300 (JP/US)
    B7-H3-directed ADC
    ESCC, CRPC, squamous NSCLC, SCLC, etc.
  • DS-6000 (JP/US)
    CDH6-directed ADC
    Renal cell carcinoma, ovarian cancer
  • DS-1055 (JP/US)
    Anti-GARP antibody
    Solid tumors
  • DS-1594 (US)
    Menin-MLL binding inhibitor
    AML, ALL
  • DS-9606 (US/EU)
    Target undisclosed ADC
    Solid tumors
  • DS-6016 (JP)
    Anti-ALK2 antibody
    FOP
  • DS-7011 (US)
    Anti-TLR7 antibody
    Systemic lupus erythematosus
  • DS-2325 (US)
    KLK5 inhibitor
    Netherton syndrome

Phase 2

  • Valemetostat (DS-3201) (JP/US/EU/Asia)
    EZH1/2 inhibitor
    PTCL
  • Valemetostat (DS-3201) (EU)
    EZH1/2 inhibitor
    BCL
  • DS-1001 (JP)
    Mutant IDH1 inhibitor
    Glioma
  • DS-7300 (JP/US/EU/Asia)
    B7-H3-directed ADC
    ES-SCLC
  • DS-5141 (JP)
    ENA oligonucleotides DMD
  • DS-1211 (US/EU)
    TNAP inhibitor
    Pseudoxanthoma elasticum
  • DS-5670 (JP)
    COVID-19 mRNA vaccine
    COVID-19 (primary vaccination, 5 to 11 aged children) (in prep.)
  • VN-0200 (JP)
    RS virus vaccine
    RS virus infection

Phase 3

  • Pexidartinib (JP/Asia)
    CSF-1/KIT/FLT3 inhibitor
    Tenosynovial giant cell tumor
  • Esaxerenone (JP)
    MR blocker
    Diabetic nephropathy
  • VN-0102/JVC-001 (JP)
    Measles mumps rubella
    combined vaccine
  • DS-5670 (JP)
    COVID-19 mRNA vaccine (original strain)
    COVID-19 (primary vaccination, adults)
  • DS-5670 (JP)
    COVID-19 mRNA vaccine (original strain)
    COVID-19 (primary vaccination, 12 to 17 aged children)

Submitted

  • Quizartinib (JP/US/EU)
    FLT3 inhibitor
    AML 1L
  • Mirogabalin (CN)
    α2δ ligands
    Diabetic peripheral neuropathic pain
  • VN-0107/MEDI3250 (JP)
    Live attenuated influenza vaccine nasal spray
  • DS-5670 (JP)
    COVID-19 mRNA vaccine (original strain)
    COVID-19 (booster vaccination)